Nisin Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 20.00 K
- Company Age 4 Year, 3 Months
- Last Filing with ROC 31 Mar 2022
- Open Charges ₹ 0.50 M
- Revenue Growth %
- Profit Growth 112.92%
- Ebitda 253.78%
- Net Worth 29.49%
- Total Assets 2406.50%
About Nisin Pharma
Nisin Pharma Private Limited (NPPL) is a Private Limited Indian Non-Government Company incorporated in India on 16 November 2020 (Four years and three months 8 days old ). Its registered office is in Thane, Maharashtra, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 20.00 K .
The company currently has active open charges totaling ₹0.50 M.
Swapnil Srivastava and Arun Srivastav serve as directors at the Company.
Company Details
- Location
Thane, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24230MH2020PTC350195
- Company No.
350195
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Nov 2020
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Nisin Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Swapnil Srivastava  | Director | 16-Nov-2020 | Current |
| Arun Srivastav | Director | 16-Nov-2020 | Current |
Financial Performance of Nisin Pharma.
Nisin Pharma Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 112.92% increase in profit. The company's net worth Soared by an impressive increase of 29.49%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nisin Pharma?
Unlock access to Nisin Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹0.50 M
₹0
Charges Breakdown by Lending Institutions
- Canara Bank : 0.05 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 19 Jul 2021 | Canara Bank | ₹0.50 M | Open |
How Many Employees Work at Nisin Pharma?
Nisin Pharma has a workforce of 0 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nisin Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nisin Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.